Name: Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Dosage forms and strengths
Published: 2026-09-17T18:16:06-04:00

Product information and disease description Product description Product information

Dosage forms and strengths

5 evidence topics · 4 sources

Phase 3 dose: two inserts in one injection

“The investigational dose for phase 3 trials is 2.7mg (two inserts) administered with one injection.” (opens the source at this quote in a new tab)
“DURAVYU dosing consists of 2 inserts delivered in a single injection.” (opens the source at this quote in a new tab)
“1343 µg/insert” (opens the source at this quote in a new tab)

Phase 3 dose as registered

Field	Quoted record
Experimental arm	“EYP-1901 2686 µg”
Route	“Intravitreal Injection”

Insert composition

“EYP-1901 intravitreal insert contains vorolanib as the active ingredient and polyvinyl alcohol as an excipient.” (opens the source at this quote in a new tab)

“94% drug / 6% matrix” (opens the source at this quote in a new tab)
“No cold storage required unlike approved biologics; pre-loaded IVT syringe injector” (opens the source at this quote in a new tab)

“This formulation allows the solid insert to deliver a higher payload of drug (94%) for sustained delivery until the drug is fully released from the insert.” (opens the source at this quote in a new tab)

Phase 2 DAVIO 2 dose strengths and applicator configuration

Dose (μg)	Number of inserts per single applicator	Needle gauge	Insert length (mm)
“2,060”	“2”	“22”	“8”
“3,090”	“3”	“22”	“8”

Storage conditions in clinical trials

“EYP-1901 must be stored in a secure place and at controlled room temperature (20°C to 25°C/68°F to 77°F) and in the original container to protect the product from light. Temperature excursions between 15°C to 30°C/59°F to 86°F are acceptable.” (opens the source at this quote in a new tab)